Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
44 hedge funds and large institutions have $90.3M invested in Forte Biosciences in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
16% more funds holding
Funds holding: 38 → 44 (+6)
1% more capital invested
Capital invested by funds: $89.2M → $90.3M (+$1.12M)
0% less ownership
Funds ownership: 0.1% → 0.1% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.98M |
| 2 |
JP Morgan Chase
New York
|
+$2.59M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.13M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
+$441K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$5.46M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.57M |
| 3 |
DAM
Doheny Asset Management
Los Angeles,
California
|
-$1.87M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.2M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$940K |
FBRX Hedge Fund Activity: Q3 2017 in Review
44 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2017, worth a combined $90.3M — up 1.3% from $89.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FBRX positions and 4 closed out — a net gain of 6 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $2.98M. The largest seller was Foresite Capital Management III, cutting an estimated $5.46M.
- 44 institutional investors held Forte Biosciences (FBRX) as of Q3 2017, up from 38 in Q2 2017.
- Funds reported $90.3M of Forte Biosciences stock for Q3 2017, up 1.3% quarter-over-quarter.
- 10 funds opened new Forte Biosciences positions in Q3 2017 and 4 closed out, a net change of +6 holders.
- The largest Forte Biosciences buyer in Q3 2017 was Acuta Capital Partners, an estimated $2.98M added.
- The largest Forte Biosciences seller in Q3 2017 was Foresite Capital Management III, an estimated $5.46M sold.
Based on aggregated 13F filings for Q3 2017.